Expression of NAD(P)H Oxidase Subunits and Their Contribution to Cardiovascular Damage in Aldosterone/Salt-Induced Hypertensive Rat by Park, Young Mee et al.
INTRODUCTION
Growing evidence has emerged to show that aldosterone
plays an independent role in the development of cardiovas-
cular organ damage. Aldosterone/salt imbalance is detrimen-
tal to patients with hypertension (1), atherosclerosis (2), and
heart failure (3) and it can lead to progressive tissue damage
in the heart, vasculature, and kidneys (1). The role of aldos-
terone in the pathogenesis of cardiovascular disease in humans
was convincingly established by results of the Randomized
Aldactone Evaluation Study (RALES) (3), and the EPlerenone
neuroHormonal Efficacy and SUrvival Study (EPHESUS)
(4). The mechanism by which aldosterone dysregulation may
contribute to cardiovascular disease is complex. Several fac-
tors have been proposed to explain the negative effects of
aldosterone on cardiac fibroblasts and myocytes, and vascu-
lar endothelial and smooth muscle cells of the cardiovascu-
lar system, including pro-inflammatory and pro-oxidative
properties (5). The pro-inflammatory and pro-fibrotic effect
of aldosterone induces target cell and organ to be damaged
structurally, functionally and mechanically, in particular due
to aldosterone induced oxidative stress via modulation of
NAD(P)H oxidase (6).
Activation of vascular NAD(P)H oxidase is a major source
of vascular reactive oxygen species (ROS). We and others have
demonstrated that increased ROS is associated with aldos-
terone-mediated cardio, renal, and vascular damage in rats
(7-10). Aldosterone has a direct effect on oxidative stress
through its ability to increase the levels of p22phox, an major
subunit of NAD(P)H oxidase, essential for superoxide anion
generation (9, 11). Further, gp91phox and 3-nitrotyrosine in
heart (7, 8), p22phox, Nox-4, and gp91phox in kidney (10), and
p22phox in aorta (9) were increased in aldosterone/salt rats.
Therefore, these data suggest the possibility that at least some
of the aldosterone-salt-induced ROS production in the tar-
get organs are mediated through the NAD(P)H oxidase path-
way. Most studies were performed in in vitro conditions. In
the present study, we questioned whether NAD(P)H oxi-
dase subunit expression and activity are modulated by aldos-
terone in vivo and assessed whether this is associated with tar-
get-organ damage in aldosterone-dependent hypertension.  
MATERIALS AND METHODS
Animal experiments 
The study was conducted according to recommendations
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Expression of NAD(P)H Oxidase Subunits and Their Contribution to
Cardiovascular Damage in Aldosterone/Salt-Induced Hypertensive Rat
NAD(P)H oxidase plays an important role in hypertension and its complication in
aldosterone-salt rat. We questioned whether NAD(P)H oxidase subunit expression
and activity are modulated by aldosterone and whether this is associated with tar-
get-organ damage. Rats were infused with aldosterone (0.75 μ g/hr/day) for 6 weeks
and were given 0.9% NaCl±losartan (30 mg/kg/day), spironolactone (200 mg/kg/
day), and apocynin (1.5 mM/L). Aldosterone-salt hypertension was prevented com-
pletely by spironolactone and modestly by losartan and apocynin. Aldosterone
increased aortic NAD(P)H oxidase activity by 34% and spironolactone and losar-
tan inhibited the activity. Aortic expression of the subunits p47
phox, gp91
phox, and p22
phox
increased in aldosterone-infused rats by 5.5, 4.7, and 3.2-fold, respectively, which
was decreased completely by spironolactone and partially by losartan and apoc-
ynin. Therefore, the increased expression of NAD(P)H oxidase may contribute to
cardiovascular damage in aldosterone-salt hypertension through the increased
expression of each subunit.
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Research Institute and Use Committee. Male Sprague-Daw-
ley rats (Charles River Laboratory, Yokohama, Japan), aged 8
weeks and weighing 250 g were studied. Sham-operated
rats served as control. Rats underwent right uninephrecto-
my via flank incision. In sham-operated or aldosterone group,
rats under anesthesia with ketamine 50 mg/kg and xylazine
5 mg/kg given intramuscularly, were implanted subcutaneous-
ly a model 2002 mini-osmotic pump (Alza Corporation, Palo
Alto, CA, U.S.A.) that infuses 0.5 μ L/hr for 6 weeks. The
mini-osmotic pumps were replaced every 2 weeks under
anesthesia. The mini-osmotic pumps infused subcutaneously
0.75 μ g/hr/day aldosterone (Sigma Chemical Co., St. Louis,
MO, U.S.A.) dissolved in 0.9% saline or saline alone. Six
aldosterone-salt rats received losartan (30 mg/kg per day) to
block angiotensin II type I receptor. Losartan was added to
the drinking water. Six aldosterone-salt rats were treated with
spironolactone (200 mg/kg per day in food). Finally, six aldos-
terone-salt rats received apocynin (1.5 mM/L) to block activ-
ity of NAD(P)H oxidase. Apocynin was added to the drink-
ing water (approximately 300 μ M/day). All rats were offered
0.9% saline to drink. Systolic blood pressure (BP) was mea-
sured weekly by the tail-cuff method and recorded by a com-
puterized BP monitor (IITT Model 31 NIBP software, IITC
Inc. Life Science, Woodland Hills, CA, U.S.A.). Rats were
sacrificed at the end of the experiment and heart and kidney
wet weights measured. The aorta, heart and kidney were care-
fully removed, cleaned of excess fat and adventitia, and placed
in PSS composed of (mM/L) NaCl 130, KCl 4.7, KH2PO4
1.18, MgSO4∙7H2O 1.17, NaHCO3 14.9, dextrose 5.5,
EDTA 0.26, and CaCl2 1.6.
NAD(P)H oxidase activity
Aortic homogenate was prepared on ice in lysis buffer con-
taining protease inhibitors (20 mM/L monobasic potassium
phosphate (pH 7.4), 1 mM/L EGTA, 10 μ g/mL aprotinin,
0.5 μ g/mL leupeptin, 0.7 μ g/mL pepstatin, and 0.5 mM/L
phenylmethylsulfonyl fluoride). Protein content was mea-
sured. Activity of NAD(P)H oxidase was measured by luci-
genin-enhanced chemiluminescent detection of superoxide in
a luminometer (MicroLumatPlus LB 96V, Berthold). The
reaction was initiated by the addition of 150 μ g of total pro-
tein to a 50 mM/L phosphate buffer, pH 7.4, containing 1
mM/L EGTA, 150 mM/L sucrose, 5 μ M/L lucigenin as the
electron acceptor, and 100 μ M/L NADPH as the substrate. 
Dihydroethidium labeling for superoxide detection 
To measure ROS production in frozen cross sections of
kidney were stained with dihydroethidium (DHE [10 μ M/
L]). In the presence of O2
-, DHE is converted to the fluores-
cent molecule ethidium, which can then label nuclei by inter-
calating with DNA. Fresh-frozen cross sections of kidney
(15 μ m) were stained with 10 μ M DHE (Sigma). 
Real-time PCR analysis 
Total RNA was isolated from aorta and kidney using TR-
IZOL (Invitrogen, Carlsbad, CA, U.S.A.). cDNA was syn-
thesized using SuperscriptTM‚ III RNase H
- reverse transcrip-
tase (Invitrogen) and 5 μ g of total RNA primed with oligo-
dT primer. After reverse transcription of RNA into cDNA,
real-time polymerase chain reaction (PCR) was performed
with Assay-on-DemandTM‚ Gene Expression products con-
sist of a 20× mix of unlabeled PCR primers on Taqman
�
MGB probe (FAMTM‚ dye-labeled) for the target sequences
(p47phox, gp91phox, and p22phox) using the ABI Prism
� 7000
Sequence Detection System (Applied Biosystems, Foster
City, CA, U.S.A.). Housekeeping genes, glyceraldehyde-3-
phosphate dehydrogenase, standardized the numbers. Quan-
tification and comparison of mRNA levels between aldos-
terone infused groups were performed by using the compar-
ative Ct method as described by manufacture. 
Immunohistochemistry
Small blocks of aorta and kidney from rats were embed-
ded in O.C.T. Tissue-Tek
� (Sakura Finetek, Torrance, CA,
U.S.A.) and frozen at -70℃. Sections of 5 μ m were cut, and
immunohistochemistry was performed with standard tech-
niques. Briefly, sections were blocked in 20% horse serum
and then incubated overnight (in a humidified box) at 4℃
with a monoclonal antibody against p47phox. For negative
control, the primary antibody was replaced with mouse IgG.
Biotinylated anti-mouse (DAKO, Carpinteria, CA, U.S.A.)
at a dilution of 1:100 in 1.5% horse serum was incubated
for 30 min followed by streptavidin conjugated to horseradish
peroxidase. Color was developed by the addition of DAB
(DAKO). The sections were lightly stained in hematoxylin.
Statistics
All data analyses were performed with SPSS 10.0 for Win-
dows programs. NAD(P)H oxidase activity and Real-time
PCR analyses were performed in duplicate. Results are pre-
sented as mean±SD and are compared by ANOVA or by
Student t test, where appropriate. The Tukey correction was
used to compensate for multiple testing. A value of p<0.05
was considered significant.
RESULTS
Systolic blood pressure, heart and kidney weight
The systolic BP of aldosterone-infused rats was significant-
ly higher than that of controls (222±14 vs. 123±9 mm
1040 Y.M. Park, B.H. Lim, R.M. Touyz, et al.Hg; p<0.01 vs. control). Spironolactone normalized BP to
103±21 mmHg. Aldosterone-mediated elevation of BP
was partially decreased by losartan and apocynin during the
experiment (170±15 and 189±20 mmHg respectively, at
6 week) (Fig. 1). Body, heart and kidney weight are summa-
rized in Table 1. Aldosterone infusion significantly increased
the heart/body weight ratio, which was decreased complete-
ly by co-treatment with spironolactone and less so by losar-
tan and apocynin. Similar results were observed in kidneys.
NAD(P)H oxidase-dependent superoxide generation in
aldosterone-salt rats.
NAD(P)H oxidase activity, a major source of superoxide
anion in the vasculature, was increased in aorta of aldosterone-
infused rats (75±3 relative light unit [RLU] stimulated by
NAD(P)H; p<0.01 vs. control) compared with controls (56
±4 RLU). Losartan and spironolactone significantly inhib-
ited NAD(P)H oxidase activity in aorta (53±13 and 44±
14.7 RLU) (Fig. 2A). To confirm the effect of NAD(P)H oxi-
dase on O2
- generation, dihydroethidium (DHE [10 μ M/L])
was compared in kidney. Aldosterone treatment significant-
ly increased the fluorescent signal in the kidney compared
with controls. This increase was normalized by treatment
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Fig. 1. Systolic BP of aldosterone-infused hypertensive rats was
slightly but significantly elevated relative to that of normotensive
control rats after 6 weeks of treatment, and showed further ele-
vation thereafter. Administration of spironolactone treatment pre-
vented development of hypertension. Losartan and apocynin
showed a trend of decrease. 
*, p<0.01 aldosterone vs. aldosterone+losartan or aldosterone+
spironolactone or aldosterone+apocynin; 
� , p<0.01 aldosterone+
spironolactone vs. aldosterone+losartan or aldosterone+apoc-
ynin (mean±SEM). 
*, p<0.01 vs. control rats; 
�
, p<0.05; 
�
, p<0.01 vs. aldosterone-infused rats.
BW, body weight; HW, heart weight; LVW and RVW, left and right ventricular weight.
Parameter BW (gm) HW (gm)
LV+RV/BW 
(×10
-3)
LV/BW
(×10
-3)
RV/BW
(×10
-3)
Kidney/BW
(×10
-3)
Sham (n=7) 417±28 1.14±0.07 2.52±0.04 1.95±0.14 0.58±0.04 4.81±0.22
Aldosterone (n=4) 322±45 1.25±0.12* 3.92±0.32* 3.19±0.28* 0.73±0.07* 11.17±1.8*
Aldosterone+losartan (n=6) 360±12 1.25±0.09 3.47±0.22
� 2.84±0.19 0.63±0.04
� 8.02±0.23
�
Aldosterone+spironolactone (n=6) 399±21
� 1.04±0.06
� 2.26±0.13
� 2.02±0.09
� 0.58±0.06
� 4.63±0.68
�
Aldosterone+apocynin (n=6) 354±32 1.19±0.15 3.32±0.12
� 2.68±0.11
� 0.61±0.04
� 7.72±1.48
�
Table 1. Physiological parameters from aldosterone-infused rats treated with or without losartan or spironolactone or apocynin
Fig. 2. NAD(P)H oxidase activity is increased in aorta from aldos-
terone-infused rats. (A) Activity of NAD(P)H oxidase in aortic seg-
ments from aldosterone-infused rats were detected by lucigenin
chemiluminescence. *, p<0.01 vs. control rats; 
� , p<0.05 vs. aldos-
terone-infused rats. (B) Aldosterone-indused superoxide (O2
-)
production is attenuated in kidney of spironolactone, losartan and
apocynin treated rats. O2
- levels were determined by fluorescent
dihydroethidium (DHE [10 μ M/L]) and visualized by confocal
microscopy. Arrow indicates intense O2
- production. 
RLU, relative light units.
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�with spironolactone and less prominently by treatment with
losartan and apocynin (Fig. 2B).
mRNA expression of NAD(P)H oxidase subunits
To determine whether increased NAD(P)H-oxidase activ-
ity was reflected at the molecular level, real-time PCR was
used to compare mRNA expression of the NAD(P)H oxi-
dase subunits, p47phox, p22phox, and gp91phox in aorta and kid-
ney from aldosterone infused rats. Aldosterone-salt rats showed
significantly higher p47phox and gp91phox expression in aorta
than that of control rats. Spironolactone significantly decreased
p47phox and gp91phox mRNA expression. Losartan and apoc-
ynin showed a trend of decrease in aorta (Fig. 3A). In kid-
ney, aldosterone-salt rats showed significantly higher p47phox,
gp91phox, and p22phox expression than that of control rats.
Spironolactone and losartan significantly decreased p47phox,
gp91phox, and p22phox mRNA expression. Apocynin showed
a trend of decrease in kidney (Fig. 3B).
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Fig. 4. Immunostaining for NAD(P)H oxidase subunit, p47
phox in aorta (A) and kidney (B) of control rats, aldosterone-salt rat, aldosterone-salt
rat treated with losartan, spironolactone and apocynin. (A) The expression of p47
phox was increased in aorta of aldosterone-infused rats.
Spironolactone significantly decreased p47
phox expression in aorta of aldosterone-infused rats. (B) The expression of p47
phox was increased
in kidney aldosterone-infused rats. Spironolactone significantly decreased p47
phox expression in aorta of aldosterone-infused rats.
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Fig. 3. Treatment with spironolactone attenuated NAD(P)H oxidase mRNA expression in aorta (A) and kidney (B) of aldosterone-infused
rats. The mRNA expression of the NAD(P)H oxidase subunits p47
phox, gp91
phox, and p22
phox was markedly increased in aldosterone-infused
rats. The treatment with spironolactone significantly reduced NAD(P)H oxidase subunits mRNA expression. Losartan and apocynin
decreased NAD(P)H oxidase subunits mRNA expression in aorta and kidney from aldosterone-infused rats. *, p<0.05 vs. control rats; 
� , p<
0.05 vs. aldosterone-infused rats.
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�Increased expression of p47
phox in aldosterone-infused rat
by immunohistochemistry 
Finally, we examined the effect of aldosterone infusion on
the subcellular distribution of p47phox in aorta and kidney.
Immunostaining showed a significant increase in p47phox in
the whole aorta of aldosterone-salt rat compared with that of
control (Fig. 4A). The aldosterone-induced p47phox overex-
pression was prevented by spironolactone, and partially by
losartan and apocynin. The p47phox expression enhanced in
kidney of aldosterone infused rats compared with that of con-
trol rats. Spironolactone, losartan, and apocynin inhibited the
aldosterone-stimulated p47phox expression in kidney (Fig. 4B).
DISCUSSION
We previously found that aldosterone infusion into nor-
motensive rats significantly increases blood pressure and
induces arterial remodeling (12), cardiac hypertrophy and
fibrosis (1), in part through ROS. Our present results demon-
strate a critical role of NAD(P)H oxidase and its subunits,
p47phox, gp91phox, and p22phox for the vascular oxidant stress
response to aldosterone. This activation in NAD(P)H oxi-
dase was abrogated by aldosterone antagonism, and partial-
ly reduced by angiotensin II receptor blockade (ARB) and
NAD(P)H oxidase inhibition. These results suggest that
aldosterone-dependent hypertension and associated target
organ damage is mediated by NAD(P)H oxidase-derived
ROS. Activation of angiotensin receptor may also contribute
to BP elevating effects of aldosterone.
Aldosterone administration in rats increases vascular O2
-
formation. A specific pro-oxidative effect of aldosterone, medi-
ated through NAD(P)H oxidase was demonstrated in circu-
lating blood cells and in aortic cells (2, 9). The overactivity
of NAD(P)H oxidase, a major determinant of vascular tissue
redox state, is associated with upregulation of p22phox mRNA,
a major subunit of the enzyme, which results in impaired
NO-dependent relaxation and media hypertrophy in SHR
(13), stroke-prone SHR (SHRsp) (14, 15), DOCA-salt rat
(16), angiotensin II-treated rats (17, 18), or aldosterone hyper-
tensive rat (9, 19). Although p22phox alone does not support
superoxide production but it has been clearly shown to sta-
bilize the expression of gp91phox (20) and Nox1 (21) in cul-
ture, probably serving as a stabilizing and/or regulatory sub-
unit. p22phox overexpression in transgenic (Tg) mice (Tgp22smc)
that overexpress the p22phox subunit of NAD(P)H oxidase
selectively in smooth muscle, concomitantly upregulates
Nox1, and potentates angiotensin II induced vascular hyper-
trophy (22). And the complete inhibition of p22phox mRNA
expression by stable transfection of antisense p22phox cDNA
into vascular smooth cells results in a significant inhibition
of angiotensin II-stimulated NADH/NADPH-dependent
superoxide production, subsequent hydrogen peroxide pro-
duction, and (3H)leucine incorporation (17). Therefore, p22phox
is a critical component of superoxide-generating vascular
NADH/NADPH oxidase and suggest a central role for this
oxidase system in vascular hypertrophy. 
Likewise, p47phox is the protein that carries the cytosolic
proteins to the membrane proteins to assemble the active
oxidase. The p47phox subunit has been shown to be essential
for ROS production in response to phorbol ester (PMA),
AngII, thrombin, and platelet-derived growth factor in vas-
cular smooth muscle cells (23, 24) and tumor necrosis factor
alpha (TNF-α ) and PMA in endothelial cell (25). In the pre-
sent study, we have shown that aldosterone treatment induced
overexpression of two membrane-bound elements (p22phox
and gp91phox) and one cytosolic component (p47phox) of the
NAD(P)H oxidase and its activity, and led to the transloca-
tion of the cytosolic p47phox to the plasma membrane in aorta
and kidney. The p22phox may individually interact with cytoso-
lic regulatory elements, p47phox and Rac-1, and therefore, both
increased expression of p22phox and p47phox will lead to activa-
tion of the enzyme. These findings are consistent with the
concept that the translocation of p47phox to membrane is
involved in the overall activation of NDA(P)H oxidase, result-
ing in O2
- production in aorta and kidney. Similarly, aldos-
terone infusion showed elevated renal tissue ROS levels which
were associated with increased mRNA expression of p22phox,
Nox-4, and gp91phox (10). And in addition to (NAD(P)H)
oxidase pathway, the angiotensin-converting enzyme (ACE)/
epidermal growth factor receptor (EGFR)/extracellular sig-
nal-regulated kinases (ERK) pathway, were known to con-
tribute to the pathogenesis of aldosterone/salt-induced hyper-
tensive rats (26). Even with chronic administration of sub-
depressor doses of spironolactone (20 mg/kg/day), perivas-
cular fibrosis and coronary microvascular hyperplasia were
ameliorated in these models, by blocking ACE/EGFR/ERK
pathway, NAD(P)H oxidase/LOX-1 pathway, and Rho-kinase
pathway (26). And spironolactone blocked connective tissue
growth factor (CTGF) expression which was inducted via
p38MAPK by aldosterone in ventricular myocytes (27). This
could, at least, explain that anti-aldosterone therapy have car-
diovascular protective effects beyond lowering blood pressure. 
In the present study, a total blockade of the pro-oxidative
effects of aldosterone on aortic segments and kidney was
obtained only when the rats were treated with a mineralocor-
ticoid receptor antagonist, spironolactone, which prevented
oxidative stress increase, overexpression of NAD(P)H oxidase
subunits and BP elevation. The ability of spironolactone to
prevent oxidative stress in arterial walls could be linked to
the amelioration of target organ damage (28). The underly-
ing mechanism of anti-oxidative blood pressure lowering
effects of spironolactone can be explained through its potent
inhibitory effects on NAD(P)H oxidase activity. In our exper-
iment and others (29), NAD(P)H oxidase inhibitor, apoc-
ynin, attenuated development of hypertension and cardio-
renal hypertrophy, with partially decreasing NAD(P)H oxi-
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oxide dismutase mimetic, to examine the possible contribu-
tion of superoxide to aldosterone-induced blood pressure
elevation and cardiac damage. It blocked blood pressure rise
by aldosterone infusion, but failed to inhibit cardiac hyper-
trophy, inflammatory lesions, and osteopontin gene expres-
sions. Of note, in contrast to apocynin and tempol, N-acetyl-
cysteine, significantly prevented aldosterone-induced cardiac
hypertrophy and inflammation, and osteopontin gene expres-
sion (30). N-acetylcysteine is a precursor of L-cysteine and a
source of sulfhydryl groups in cells and act as a scavenger of
free radicals such as hydroxyl radical (OH ∙) and hydrogen
peroxide (H2O2) but not superoxide. Recently, we have shown
that the increased vascular oxidative stress in mineralocorti-
coid-salt model was associated with activation of the endothe-
lin (ET) system via endothelin A receptor pathways (12, 31),
showing that endothelin and ROS was identified as impor-
tant mediators in the pathogenesis of hypertension and asso-
ciated vascular damage. In the following study, it was found
that endothelin stimulates mitochondria to generate ROS,
which is independent to activation of eNOS in the vascular
wall (32). Therefore, these can explain less effects of apocynin
in this model. However, a clear explanation on this mecha-
nism is still not available, and therefore, further studies are
needed to elucidate the detailed role of oxidative stress in
aldosterone-induced cardiac injury. 
ARB was thought to protect against its detrimental effects
on target organs, including the cardiovascular system. Although
ARB reduces aldosterone levels initially, the suppression of
aldosterone is variable and rebound or escape over the long
term (33). If not inhibited by ARB, residual aldosterone can
cause a wide range of pathophysiologic action and compound
the effects of angiotensin II and other products of the RAAS.
In some experiment, RAS blocker with either losartan or
enalapril did not prevent hypertension development and renal
injury in uninephrectomized aldosterone-salt rat (34). Sec-
ondly, in our previous experiment, ET-1 was a critical role
for the BP elevation and structural alterations of vessels and
heart in aldosterone and salt-induced hypertension. There-
fore, ARB can’t be enough to block the elevated ET-1 in this
model (12). Lastly, the usual dose of ARB has no or partial
effect on blood pressure or proteinuria and they need ultra-
high dose of ARB to ameliorate the progression of aldos-
terone/salt-dependent renal injury. As shown in this study,
losartan partially reduced target organ damage in aldos-
terone-salt rat. 
In conclusion, we have presented strong evidence for the
pro-oxidative properties of aldosterone in aorta and kidney
in aldosterone-salt rat. Furthermore, we demonstrated that
aldosterone activated NAD(P)H oxidase and increased the
expression of membrane-bound elements (p22phox and gp91phox)
and cytosolic components (p47phox) of the enzyme, which
may be linked to cardio-vascular-renal damage. This effect
is mediated, at least in part, by the mineralocorticoid recep-
tor, because aldosterone blockade completely prevented BP
elevation, increased production of oxidative stress, hypertro-
phy. Partial beneficial effect of angiotensin II receptor block-
ade or NAD(P)H oxidase inhibition suggest that co-treat-
ment of aldosterone antagonist with angiotensin receptor or
NAD(P)H oxidase blockade may enhance beneficial anti-
oxidative effects and thereby better protect against target
organ damage associated with hypertension. 
REFERENCES
1. Park JB, Schiffrin EL. Cardiac and vascular fibrosis and hypertro-
phy in aldosterone-infused rats: role of endothelin-1. Am J Hyper-
tens 2002; 15: 164-9.
2. Keidar S, Kaplan M, Pavlotzky E, Coleman R, Hayek T, Hamoud
S, Aviram M. Aldosterone administration to mice stimulates macro-
phage NADPH oxidase and increases atherosclerosis development:
a possible role for angiotensin-converting enzyme and the receptors
for angiotensin II and aldosterone. Circulation 2004; 109: 2213-20.
3. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palen-
sky J, Wittes J. The effect of spironolactone on morbidity and mor-
tality in patients with severe heart failure. Randomized Aldactone
Evaluation Study Investigators. N Engl J Med 1999; 341: 709-17.
4. Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, Bittman
R, Hurley S, Kleiman J, Gatlin M; Eplerenone Post-Acute Myocar-
dial Infarction Heart Failure Efficacy and Survival Study Investiga-
tors. Eplerenone, a selective aldosterone blocker, in patients with
left ventricular dysfunction after myocardial infarction. N Engl J
Med 2003; 348: 1309-21.
5. Losel R, Schultz A, Boldyreff B, Wehling M. Rapid effects of aldos-
terone on vascular cells: clinical implications. Steroids 2004; 69:
575-8.
6. Oberleithner H. Aldosterone makes human endothelium stiff and
vulnerable. Kidney Int 2005; 67: 1680-2.
7. Sun Y, Zhang J, Lu L, Chen SS, Quinn MT, Weber KT. Aldosterone-
induced inflammation in the rat heart: role of oxidative stress. Am J
Pathol 2002; 161: 1773-81.
8. Gerling IC, Sun Y, Ahokas RA, Wodi LA, Bhattacharya SK, War-
rington KJ, Postlethwaite AE, Weber KT. Aldosteronism: an immu-
nostimulatory state precedes proinflammatory/fibrogenic cardiac
phenotype. Am J Physiol Heart Circ Physiol 2003; 285: H813-21.
9. Park YM, Park MY, Suh YL, Park JB. NAD(P)H oxidase inhibitor
prevents blood pressure elevation and cardiovascular hypertrophy
in aldosterone-infused rats. Biochem Biophys Res Commun 2004;
313: 812-7.
10. Nishiyama A, Yao L, Nagai Y, Miyata K, Yoshizumi M, Kagami
S, Kondo S, Kiyomoto H, Shokoji T, Kimura S, Kohno M, Abe Y.
Possible contributions of reactive oxygen species and mitogen-acti-
vated protein kinase to renal injury in aldosterone/salt-induced
hypertensive rats. Hypertension 2004; 43: 841-8.
11. Calo LA, Zaghetto F, Pagnin E, Davis PA, De Mozzi P, Sartorato
P, Martire G, Fiore C, Armanini D. Effect of aldosterone and gly-
cyrrhetinic acid on the protein expression of PAI-1 and p22(phox)
1044 Y.M. Park, B.H. Lim, R.M. Touyz, et al.in human mononuclear leukocytes. J Clin Endocrinol Metab 2004;
89: 1973-6.
12. Park JB, Schiffrin EL. ET(A) receptor antagonist prevents blood
pressure elevation and vascular remodeling in aldosterone-infused
rats. Hypertension 2001; 37: 1444-9.
13. Zalba G, Beaumont FJ, San Jose G, Fortuno A, Fortuno MA, Etayo
JC, Diez J. Vascular NADH/NADPH oxidase is involved in enhanced
superoxide production in spontaneously hypertensive rats. Hyper-
tension 2000; 35: 1055-61.
14. Chen X, Touyz RM, Park JB, Schiffrin EL. Antioxidant effects of
vitamins C and E are associated with altered activation of vascular
NADPH oxidase and superoxide dismutase in stroke-prone SHR.
Hypertension 2001; 38: 606-11.
15. Park JB, Touyz RM, Chen X, Schiffrin EL. Chronic treatment with
a superoxide dismutase mimetic prevents vascular remodeling and
progression of hypertension in salt-loaded stroke-prone spontaneous-
ly hypertensive rats. Am J Hypertens 2002; 15: 78-84.
16. Somers MJ, Mavromatis K, Galis ZS, Harrison DG. Vascular super-
oxide production and vasomotor function in hypertension induced
by deoxycorticosterone acetate-salt. Circulation 2000; 101: 1722-8.
17. Ushio-Fukai M, Zafari AM, Fukui T, Ishizaka N, Griendling KK.
p22phox is a critical component of the superoxide-generating NADH/
NADPH oxidase system and regulates angiotensin II-induced hyper-
trophy in vascular smooth muscle cells. J Biol Chem 1996; 271:
23317-21.
18. Fukui T, Ishizaka N, Rajagopalan S, Laursen JB, Capers Q 4th, Tay-
lor WR, Harrison DG, de Leon H, Wilcox JN, Griendling KK. p22phox
mRNA expression and NADPH oxidase activity are increased in
aortas from hypertensive rats. Circ Res 1997; 80: 45-51.
19. Beswick RA, Dorrance AM, Leite R, Webb RC. NADH/NADPH
oxidase and enhanced superoxide production in the mineralocorti-
coid hypertensive rat. Hypertension 2001; 38: 1107-11.
20. Griendling KK, Ushio-Fukai M. Reactive oxygen species as media-
tors of angiotensin II signaling. Regul Pept 2000; 91: 21-7.
21. Hanna IR, Hilenski LL, Dikalova A, Taniyama Y, Dikalov S, Lyle
A, Quinn MT, Lassegue B, Griendling KK. Functional association
of nox1 with p22phox in vascular smooth muscle cells. Free Radic
Biol Med 2004; 37: 1542-9.
22. Weber DS, Rocic P, Mellis AM, Laude K, Lyle AN, Harrison DG,
Griendling KK. Angiotensin II-induced hypertrophy is potentiated
in mice overexpressing p22phox in vascular smooth muscle. Am J
Physiol Heart Circ Physiol 2005; 288: H37-42.
23. Lavigne MC, Malech HL, Holland SM, Leto TL. Genetic demon-
stration of p47phox-dependent superoxide anion production in murine
vascular smooth muscle cells. Circulation 2001; 104: 79-84.
24. Barry-Lane PA, Patterson C, van der Merwe M, Hu Z, Holland SM,
Yeh ET, Runge MS. p47phox is required for atherosclerotic lesion
progression in ApoE(-/-) mice. J Clin Invest 2001; 108: 1513-22.
25. Li JM, Mullen AM, Yun S, Wientjes F, Brouns GY, Thrasher AJ,
Shah AM. Essential role of the NADPH oxidase subunit p47(phox)
in endothelial cell superoxide production in response to phorbol
ester and tumor necrosis factor-alpha. Circ Res 2002; 90: 143-50.
26. Nakano S, Kobayashi N, Yoshida K, Ohno T, Matsuoka H. Cardio-
protective mechanisms of spironolactone associated with the angi-
otensin-converting enzyme/epidermal growth factor receptor/extra-
cellular signal-regulated kinases, NAD(P)H oxidase/lectin-like oxi-
dized low-density lipoprotein receptor-1, and Rho-kinase pathways
in aldosterone/salt-induced hypertensive rats. Hypertens Res 2005;
28: 925-36. 
27. Lee YS, Kim JA, Kim KL, Jang HS, Kim JM, Lee JY, Shin IS, Lee
JS, Suh W, Choi JH, Jeon ES, Byun J, Kim DK. Aldosterone upreg-
ulates connective tissue growth factor gene expression via p38 MAPK
pathway and mineralocorticoid receptor in ventricular myocytes. J
Korean Med Sci 2004; 19: 805-11.
28. Kuster GM, Kotlyar E, Rude MK, Siwik DA, Liao R, Colucci WS,
Sam F. Mineralocorticoid receptor inhibition ameliorates the tran-
sition to myocardial failure and decreases oxidative stress and inflam-
mation in mice with chronic pressure overload. Circulation 2005;
111: 420-7.
29. Zhang Y, Chan MM, Andrews MC, Mori TA, Croft KD, McKen-
zie KU, Schyvens CG, Whitworth JA. Apocynin but not allopurinol
prevents and reverses adrenocorticotropic hormone-induced hyper-
tension in the rat. Am J Hypertens 2005; 18: 910-6.
30. Yoshrida K, Kim-Mitsuyama S, Wake R, Izumiya Y, Izumi Y, Yu-
kimura T, Ueda M, Yoshiyama M, Iwao H. Excess aldosterone under
normal salt diet induces cardiac hypertrophy and infiltration via
oxidative stress. Hypertens Res 2005; 28: 447-55.
31. Callera GE, Touyz RM, Teixeira SA, Muscara MN, Carvalho MH,
Fortes ZB, Nigro D, Schiffrin EL, Tostes RC. ETA receptor block-
ade decreases vascular superoxide generation in DOCA-salt hyper-
tension. Hypertension. 2003; 42: 811-7.
32. Callera GE, Tostes RC, Yogi A, Montezano AC, Touyz RM. En-
dothelin-1-induced oxidative stress in DOCA-salt hypertension
involves NADPH-oxidase-independent mechanisms. Clin Sci (Lond)
2006; 110: 243-53. 
33. Struthers AD, MacDonald TM. Review of aldosterone- and angio-
tensin II-induced target organ damage and prevention. Cardiovasc
Res 2004; 61: 663-70.
34. Sorooshian M, Olson JL, Meyer TW. Effect of angiotensin II block-
ade on renal injury in mineralocorticoid-salt hypertension. Hyper-
tension 2000; 36: 569-74.
Aldosterone, NAD(P)H Oxidase and Organ Damage 1045